Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory viruses. - View it on GitHub